Your browser doesn't support javascript.
loading
Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
Sung, Anthony D; Hassan, Syed; Cardona, Diana M; Wild, Daniel; Nichols, Krista Rowe; Mehdikhani, Hossein; Balmadrid, Bryan; Detweiler, Claire J; Shealy, Michael; Cirrincione, Constance; Li, Zhiguo; Poleski, Martin; Dalton, Tara E; Siamakpour-Reihani, Sharareh; Chao, Nelson J; Sullivan, Keith M.
Afiliação
  • Sung AD; Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina. Electronic address: anthony.sung@duke.edu.
  • Hassan S; Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Cardona DM; Department of Pathology, Duke University, Durham, North Carolina.
  • Wild D; Division of Gastroenterology, Duke University Medical Center, Durham, NC.
  • Nichols KR; Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Mehdikhani H; Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Balmadrid B; Division of Gastroenterology, Duke University Medical Center, Durham, NC.
  • Detweiler CJ; Department of Pathology, Duke University, Durham, North Carolina.
  • Shealy M; Department of Pathology, Duke University, Durham, North Carolina.
  • Cirrincione C; Department of Biostatistics and Bioinformatics, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Li Z; Department of Biostatistics and Bioinformatics, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Poleski M; Division of Gastroenterology, Duke University Medical Center, Durham, NC.
  • Dalton TE; Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Siamakpour-Reihani S; Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Chao NJ; Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Sullivan KM; Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina.
Biol Blood Marrow Transplant ; 24(4): 734-740, 2018 04.
Article em En | MEDLINE | ID: mdl-29246821
Gastrointestinal (GI) complications including graft-versus-host disease (GVHD) are a major cause of morbidity and mortality in allogenic stem transplant recipients. Although several studies have previously looked into the acute GI complications, fewer smaller studies have reported late complications. In this large study we focus on the late (100 days post-transplant) GI complications in allogenic stem transplant recipients. In this single-center, retrospective study of all adult allogenic stem cell transplant recipients who had their transplant at Duke University over a 6-year period, 479 patients underwent allogenic stem cell transplant, of whom 392 recipients survived for at least 100 days post-transplant. Late GI symptoms were noted in 71 patients, prompting endoscopic evaluation. The primary endpoint of our study was the diagnosis of GI-GVHD based on endoscopic findings, whereas overall survival and nonrelapse mortality were the secondary endpoints. Of the 71 patients who underwent endoscopy, 45 (63%) had GI-GVHD. Of these 45 patients, 39 (87%) had late acute GVHD, 1 (2%) had chronic GVHD, and 5 patients (11%) had overlap disease. Of the patients who did not have GVHD, the symptoms were mostly related to infectious and inflammatory causes. Less common causes included drug toxicity, food intolerance, disease relapse, and motility issues. In a multivariate analysis the factors most indicative of GI-GVHD were histologic findings of apoptosis on the tissue specimen (odds ratio, 2.35; 95% confidence interval, 1.18 to 4.70; P = .015) and clinical findings of diarrhea (odds ratio, 5.43; 95% confidence interval, 1.25 to 23.54; P = .024). The median survival time from the first endoscopy was 8.5 months. The incidence of nonrelapse mortality at 6 months was 31% in patients with GI-GVHD and 19% in patients without GI-GVHD (P = .42). All patients with GI-GVHD were on steroid therapy, and 31% of them received total parenteral nutrition. In our population close to one-fifth of allogenic transplant recipients experienced late GI complications, warranting endoscopic evaluation. Most of these patients were found to have GI-GVHD that had a high incidence of nonrelapse mortality at 6 months and close to one-third of these patients needed total parenteral nutrition.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Gastroenteropatias / Doença Enxerto-Hospedeiro Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Gastroenteropatias / Doença Enxerto-Hospedeiro Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2018 Tipo de documento: Article